Exelixis, Inc. (NASDAQ:EXEL) said on Tuesday that the FDA approved its CABOMETYX tablets, for the expanded indication of patients with advanced renal cell carcinoma …
Sean Lavin: TRXC investor focus to turn to U.S.
Cowen’s Eric Schmidt sees an extra several hundred million dollars in sales for EXEL in HCC market.
Exelixis, Inc. (NASDAQ:EXEL) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 30% upturn.
Ever since Exelixis, Inc. (NASDAQ:EXEL) gained approval from the FDA allowing its pipeline drug to be released for treatment of second-line advanced renal …
Exelixis, Inc. (NASDAQ:EXEL)’s partner Genentech, a member of the Roche Group, informedExelixis that, in order to accommodate its review of a supplemental data …
Exelixis, Inc. (NASDAQ:EXEL) announced that the U.
Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and full year of 2014 and provided an update on progress toward …
(BUSINESS WIRE)–Jan. 29, 2015– Exelixis, Inc.
In a research report issued yesterday, William Blair analyst John Sonnier maintained an Outperform rating on Exelixis (NASDAQ:EXEL). No price target provided.
